These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33162753)

  • 1. Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study.
    Pedersen L; Szecsi PB; Johansen PB; Bjerrum PJ
    Biologics; 2020; 14():115-125. PubMed ID: 33162753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysis.
    Dong W; Hu X; Wu C; Wang G; Fang Y; Shi L; Nie X
    Semin Arthritis Rheum; 2023 Dec; 63():152302. PubMed ID: 37951128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022.
    Li Y; Xie C; Ding X; Wu Z; Zhang J; Zhu J; Miao L
    Front Pharmacol; 2024; 15():1376708. PubMed ID: 39040471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
    Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.
    Restellini S; Chao CY; Lakatos PL; Aruljothy A; Aziz H; Kherad O; Bitton A; Wild G; Afif W; Bessissow T
    Inflamm Bowel Dis; 2018 Jun; 24(7):1531-1538. PubMed ID: 29668893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results.
    Sagar R; Lenti MV; Clark T; Rafferty HJ; Gracie DJ; Ford AC; O'Connor A; Ahmad T; Hamlin PJ; Selinger CP
    Inflamm Intest Dis; 2021 Sep; 6(3):132-139. PubMed ID: 34722643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease.
    Gofin Y; Matar M; Shamir R; Assa A
    Inflamm Bowel Dis; 2020 Jul; 26(8):1276-1282. PubMed ID: 31634402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

  • 14. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
    Samaan MA; Arkir Z; Ahmad T; Irving PM
    Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
    Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
    Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.